Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,065 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 2Phase 3 Interventional Results available

Vaginal Estriol in Multiple Sclerosis

NCT03774407
View directory record Official record
Conditions
Multiple Sclerosis, Neurogenic Bladder
Interventions
vaginal estriol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Not listed No phase listed Observational

Cure Cystinosis International Registry

NCT01327807
View directory record Official record
Conditions
Cystinosis, Nephropathic Cystinosis, Renal Fanconi Syndrome
Interventions
Not listed
Lead sponsor
Cystinosis Research Foundation
Other
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Not applicable Interventional

Comparison of Standard of Care or Treatment on Protocol

NCT01010334
View directory record Official record
Conditions
Stomach Cancer, Esophageal Cancer, Bladder Cancer, Skin Cancer, Lung Cancer, Uterine Cancer, Ovarian Cancer
Interventions
standard of care
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NCT06800963
View directory record Official record
Conditions
NMIBC
Interventions
Intravesical Recombinant Mycobacterium (rMBCG)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Chandler, Arizona • Sacramento, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Withdrawn Not applicable Interventional

hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

NCT01026363
View directory record Official record
Conditions
Chronic Kidney Disease, Vitamin D Deficiency
Interventions
Ergocalciferol, Calcitriol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 23, 2026, 9:23 AM EDT
Enrolling by invitation No phase listed Observational

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

NCT06823115
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
0 Minutes to 2 Weeks
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Cola on Urinary Stone Risk Factors

NCT00289120
View directory record Official record
Conditions
Kidney Stone
Interventions
Cola beverage, Deionized water
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Phase 4 Interventional

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

NCT07508124
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
betamethasone valerate 0.1% cream, Placebo cream
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Months to 5 Months · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Not listed Not applicable Interventional

A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

NCT03191188
View directory record Official record
Conditions
Thyroid Disease, Kidney Diseases, Chronic
Interventions
Levothyroxine Sodium, Placebo Oral Tablet
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

NCT01163162
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Not applicable Interventional

Solv Multi-Pass Hemodialysis System In-Center Clinical Study

NCT07216885
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Solv Multi-Pass Hemodialysis System
Device
Lead sponsor
Mozarc Medical US LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143
View directory record Official record
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT02596035
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated No phase listed Observational Results available

Tracking Renal Tumors After Cryoablation Evaluation

NCT01117779
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Cryoablation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
7
States / cities
Orange, California • Denver, Colorado • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Not applicable Interventional Results available

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

NCT02247960
View directory record Official record
Conditions
Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
Interventions
Ciprofloxacin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 23, 2026, 9:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease

NCT01087255
View directory record Official record
Conditions
Chronic Kidney Disease, Medication Adherence
Interventions
Electronic Pillbox Monitoring System
Device
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

NCT01588678
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-3078a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Not applicable Interventional Results available

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

NCT01789840
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, TURP
Device · Procedure
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
50 Years to 79 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

NCT04474210
View directory record Official record
Conditions
Renal Insufficiency
Interventions
JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 9:23 AM EDT